Revenue: The sum of all revenue fields included for a company's operating activities.
Keros Therapeutics, Inc. (KROS) had Revenue of $211.25M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
|
Revenue |
$211.25M |
$148.45M |
|
-- |
|
$211.25M |
|
$59.21M |
|
$152.04M |
|
$6.45M |
|
$158.49M |
|
$158.49M |
|
$148.45M |
|
$148.45M |
|
$148.45M |
|
$148.45M |
|
$152.04M |
|
$152.38M |
|
40.56M |
|
41.02M |
|
$3.66 |
|
$3.62 |
|
| Balance Sheet Financials | |
$759.51M |
|
$4.47M |
|
$25.05M |
|
$784.56M |
|
$39.38M |
|
-- |
|
$16.31M |
|
$55.69M |
|
$728.87M |
|
$728.87M |
|
$728.87M |
|
40.56M |
|
| Cash Flow Statement Financials | |
$161.17M |
|
$-0.56M |
|
$0.00M |
|
$561.38M |
|
$721.99M |
|
$160.61M |
|
$8.86M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
19.29 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
71.97% |
|
71.97% |
|
-- |
|
75.03% |
|
70.27% |
|
$160.61M |
|
-- |
|
-- |
|
-- |
|
0.27 |
|
-- |
|
12.22 |
|
7.37 |
|
20.37% |
|
20.37% |
|
18.92% |
|
20.37% |
|
$17.97 |
|
$3.92 |
|
$3.93 |
|